| Vol. 14.39 – 3 October, 2023 |
| |
|
|
| Researchers used cholesterol-loaded Tet methylcytosine dioxygenase 2 (TET2)-deficient murine and embryonic stem cell–derived isogenic human macrophages to evaluate mechanisms of NLRP3 inflammasome activation in vitro. [Circulation] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators identified a T cell receptor reactive to the recurrent D835Y driver mutation in the FMS-related receptor tyrosine kinase 3 tyrosine kinase domain (TCRFLT3D/Y). TCRFLT3D/Y-redirected T cells selectively eliminated primary human AML cells harboring the FLT3D835Y mutation in vitro and in vivo. [Nature Cancer] |
|
|
|
| Scientists demonstrated that epitope-engineered HSPCs were shielded from CD123-targeted immunotherapy but remained functional, while CD123-deficient HSPCs displayed a competitive disadvantage. [Journal Of Experimental Medicine] |
|
|
|
| Investigators highlighted the importance of translation elongation as a driver of disease progression and identified inactivation of eEF2 activity as a novel therapeutic target for blocking chronic lymphocytic leukemia progression. [Leukemia] |
|
|
|
| Researchers tested whether reticulocytes in donor red blood cell (RBC) units could enhance RBC alloimmunization. Using a murine model, they demonstratedthat transfusing donor RBC units with increased reticulocyte frequencies dose-dependently increased RBC alloimmunization rates and alloantibody levels. [Haematologica] |
|
|
|
| Investigators showed that pharmacological inhibition of a common cis-regulatory element of forkhead box O (FOXO) family members successfully induced cell differentiation in various AML cell lines. [Cell Death & Disease] |
| |
|
|
| Scientists investigated the role of YAP during the hematopoietic differentiation of human induced pluripotent stem cells (hiPSCs) to hematopoietic stem/progenitor cells and erythrocytes using the isogenic YAP-overexpressing and YAP-depleting hiPSCs to eliminate the effects of a genetic background variation. [Stem Cell Research & Therapy] |
|
|
|
| Researchers retrospectively evaluated the outcomes of 30 patients with Fanconi anemia and myelodysplastic syndrome/AML who underwent first allogeneic hematopoietic stem cell transplantation with a T cell-depleted graft at our institution. [Bone Marrow Transplantation] |
|
|
|
| Investigators expanded cord blood-derived natural killer (CB-NK) cells ex vivo from random donors and investigated the feasibility and efficacy of repeated infusions CB-NK cells as maintenance therapy after autologous hematopoietic stem cell transplantation. [Annals Of Hematology] |
|
|
|
|
| The authors present evidence supporting that angiotensin II modulates physiological and pathological erythropoiesis processes trough the AT1 receptor. [Biochemical Pharmacology] |
|
|
|
| Scientists review the evolving views of HSPC biology during developmental and postnatal hematopoiesis. Moreover, we discuss recent advances in the in vitro induction and expansion of HSPCs, with a focus on the implications for clinical applications. [Journal Of Genetics And Genomics] |
|
|
|
| | Smart Immune announced that the first patients have been dosed in its ReSET-02 Phase I/II trial for adult acute leukemia and myelodysplasia syndrome patients. Two patients have now received the first dose level of SMART101, an allogeneic cell therapy produced from donor-mobilized peripheral blood stem cells. [Smart Immune] |
|
|
|
|
| October 23 – 25, 2023 Toronto, Ontario, Canada |
|
|
|
|
|
| University of Nebraska Medical Center – Omaha, Nebraska, United States |
|
|
|
| University of North Carolina at Chapel Hill – Chapel Hill, North Carolina, United States |
|
|
|
| Houston Methodist Research Institute – Houston, Texas, United States |
|
|
|
| Versiti Blood Research Institute, – Wisconsin Rapids, Wisconsin, United States |
|
|
|
| The Sidney Kimmel Cancer Center – Philadelphia, Pennsylvania, United States |
|
|
|
|